Redefining Clinical Outcomes in Hemophilia: The Impact of Personalized Treatment Strategies

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2018 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2018 to August 1, 2019

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Shire and CSL Behring

Description:
Hemophilia is an inherited disorder caused by a defect in one of the X chromosomes resulting in excessive bleeding and easy bruising. While females are typically carriers of the genetic defect, the majority of cases are seen in males and it’s believed that around 1 in 5,000 males are born with it every year. Bleeding can be external or internal and bleeding into the joints is especially a problem as it can cause long term damage if not treated quickly. Bleeding in the brain is an even more serious problem for those with severe hemophilia, since it can be caused by a simple head bump. Hemophilia A is more common than B and each type require different treatments. Hemophilia is diagnosed through blood tests to determine the severity of the disease and discover which clotting factor is low or missing. Replacement therapy remains the mainstay of treatment which contain concentrates of clotting factor which is infused and can be synthetic or made with human blood. Early treatment and prophylactic therapy is critical to effectively managing the disease and improving patient outcomes by preventing joint damage. Demand therapy is done on an as needed basis. Patient education is also critical as infusions can be taught to patients and done at home, alleviating unnecessary doctor appointments and lowering the cost of treatment. Replacement therapy can be taught to a capable person, and infusions can be done at home, making for quicker treatment with less stress, less visits to the doctor, and less cost.

Upon completion of this activity, participants will be able to:

  • Assess the current clinical recommendations for the management of hemophilia, including newer factor concentrates, prophylactic factor replacement strategies, and gene therapy

  • Analyze the latest safety and efficacy data of current and emerging treatments for hemophilia

  • Explore the guideline recommendations for testing and monitoring of inhibitors and joint health, including newer pharmacokinetic modeling approaches

  • Review appropriate solutions to the challenges of hemophilia management, including personalized strategies that improve patient adherence and outcomes

  • Discuss the long-term efficacy and safety assessments of current and emerging extended half-life (EHL) factor products and nonfactor replacement therapies
     

Faculty: Christopher E. Walsh, MD, PHD
Associate Professor
Director, Hemophilia Program
Division of Hematology and Medical Oncology
Mount Sinai School of Medicine
New York, New York

Disclosure:

Dr. Walsh serves as a consultant for Bioverativ, CSL Behring, Genentech, Novo Nordisk, and Shire. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Shire and CSL Behring

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue